choose content

Choose content

Enter keywords to create a newsletter
create account

Create account

Enter your registration information
set preferences

Set preferences

Set up your newsletter name, delivery and time zone preferences
Hint: Enter different keywords to generate new results.

Now you can:

  1. Search the news index.
  2. Browse more than 1 million newsletters by category.
  3. Use preset newsletters:
    • Lung Cancer & Xalkori

Lung Cancer & Xalkori Newsletter
  • PGIMER report bats for new-age targeted lung cancer therapies to be included in AB-PMJAY 29 Mar 2025 05:16 GMT

    … age targeted therapies for lung cancers—one of the top … or metastatic non-small cell lung cancer (NSCLC). These targeted … a more aggressive form of lung cancer. The health economists’ report … sold under the brand name Xalkori, and Swiss drugmaker Novartis …

  • Taletrectinib Yields Durable Responses, Prolonged PFS in ROS1+ NSCLC 18 Apr 2025 17:56 GMT

    … ROS1-positive non–small cell lung cancer (NSCLC) regardless of prior … patients who received prior crizotinib (Xalkori; n = 103) or prior … in ROS1+ non-small cell lung cancer: TRUST. J Clin Oncol. … fusions in non-small-cell lung cancer: evidence to date. Curr …

  • HLB Panagene's companion diagnostic for Pfizer’s lung cancer drug Xalkori wins approval 05 Feb 2025 05:21 GMT

    … diagnostic for Pfizer’s lung cancer-targeted therapy, Xalkori (ingredient: crizotinib). This marks … mutations in non-small cell lung cancer (NSCLC). According to global market … rate of 8.7 percent. Lung cancer, which currently accounts for 30 …

  • Top 10 Lung Cancer Advances of 2024 06 Jan 2025 20:23 GMT

    … metastatic non–small cell lung cancer (NSCLC) who have … crizotinib (Xalkori). FDA Approves Tarlatamab in Small Cell Lung Cancer: … BiTE), for small cell lung cancer (SCLC) that has progressed … represent significant strides in lung cancer research and treatment, …

  • Playing catch-up with Pfizer and Roche, China-made ALK drug clears FDA in lung cancer 19 Dec 2024 20:01 GMT

    … -positive non-small cell lung cancer among patients who’ve … the first innovative targeted lung cancer drug developed by a … Lorbrena have all outperformed Xalkori to secure their respective … JAMA Oncology. Compared with Xalkori, Ensacove reduced the risk …

  • FDA approves ensartinib for metastatic non-small cell lung cancer 19 Dec 2024 19:40 GMT

    … metastatic non-small cell lung cancer. The indication applies to … or metastatic non-small cell lung cancer. Image: Adobe Stock. … positive non-small cell lung cancer who had not previously … received ensartinib or crizotinib (Xalkori, Pfizer). PFS served as …

  • FDA Approves Ensartinib for Anaplastic Lymphoma Kinase-Positive Non-Small Cell Lung Cancer 19 Dec 2024 19:10 GMT

    … Positive Non-Small Cell Lung Cancer (NSCLC) Patients ClinicalTrials … metastatic non–small cell lung cancer (NSCLC) who have … ensartinib compared with crizotinib (Xalkori; Pfizer). A total … Positive Non-Small Cell Lung Cancer (NSCLC) Patients. ClinicalTrials …

  • Advances in the Treatment of Rare Mutations in Non-Small Cell Lung Cancer 20 Nov 2024 07:57 GMT

    … small cell lung cancer (NSCLC) and small cell lung cancer (SCLC) … -small cell lung cancer; SCLC, small cell lung cancer; EGFR, epidermal … xalkori-treat-rare-form-advanced-non-small-cell-lung-cancer. … cell lung cancer: a narrative review. Transl Lung Cancer Res. …

  • Elucidating Lorlatinib Benefit, ALK TKI Sequencing in ALK-Positive NSCLC 14 Apr 2025 15:58 GMT

    … compared lorlatinib and crizotinib (Xalkori) head-to-head, … with ALK-positive lung cancers, which proportionally encompasses … lung cancer is that unlike more smoking-associated lung cancers, ALK-positive lung cancers … in ALK-rearranged lung cancer, and there are …

  • “Unprecedented” Progression-Free Survival for ALK-Positive Lung Cancer 09 Sep 2024 17:48 GMT

    … positive metastatic non-small-cell lung cancer (NSCLC)—the longest progression- … or the older ALK inhibitor Xalkori (crizotinib) twice daily.   In … compared with 39% in the Xalkori group. Many participants were … .1 months in the Xalkori group but still has …

Satisfied with the content?

Continue to create your account.